Detta är en demosida
AboutOur team
Alexander From joined Impilo in 2022. He holds a M.Sc. in Finance from Aarhus University. During his studies he also did an exchange program at National University of Singapore.
Prior to joining Impilo, Alexander worked at FIH Partners based in Copenhagen. While at FIH Partners he was involved in several transactions in the healthcare sector.
Carolina Oscarius Dahl joined Impilo in 2023. Carolina graduated with an M.Sc. in Economics and Business Administration from the Stockholm School of Economics in 2008, with a major in Accounting and Finance.
Prior to joining Impilo, Carolina was an Investment Director at Interogo Holding Long-term Equity (2020-2022). From 2016 to 2020, Carolina worked at Nordstjernan and served on the boards of companies within the healthcare sector. Carolina started her career at McKinsey & Company (2008-2016).
Our companies
Våra siffror
Kaffekoppar per dag
Gemensam erfarenhet
bolag
Vanlig text
Aenean posuere, tortor sed cursus feugiat, nunc augue blandit nunc, eu sollicitudin urna dolor sagittis lacus. Vestibulum dapibus nunc ac augue. Maecenas nec odio et ante tincidunt tempus. Morbi nec metus.
Vivamus elementum semper nisi. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum. Phasellus magna. Nunc sed turpis.
Vestibulum suscipit nulla quis orci. Vivamus quis mi. Fusce pharetra convallis urna. Curabitur at lacus ac velit ornare lobortis.
Curabitur ligula sapien, tincidunt non, euismod vitae, posuere imperdiet, leo. Praesent vestibulum dapibus nibh. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam commodo suscipit quam.
Impilo at a glance
Rubrik
Maecenas egestas arcu quis ligula mattis placerat. Donec interdum, metus et hendrerit aliquet, dolor diam sagittis ligula, eget egestas libero turpis vel mi. Fusce vulputate eleifend sapien. Praesent porttitor, nulla vitae posuere iaculis, arcu nisl dignissim dolor, a pretium mi sem ut ipsum.
Fusce convallis metus id felis luctus adipiscing. Morbi mollis tellus ac sapien. Nam adipiscing. Vestibulum dapibus nunc ac augue.
Facts About This Company
Nunc nulla. Sed lectus. Maecenas vestibulum mollis diam.
Pellentesque libero tortor, tincidunt et, tincidunt eget, semper nec, quam. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum. Morbi mattis ullamcorper velit.
Rubrik
Phasellus dolor. Nam ipsum risus, rutrum vitae, vestibulum eu, molestie vel, lacus. Etiam ultricies nisi vel augue. Suspendisse pulvinar, augue ac venenatis condimentum, sem libero volutpat nibh, nec pellentesque velit pede quis nunc.
Vivamus euismod mauris. Duis lobortis massa imperdiet quam. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Sed cursus turpis vitae tortor.
Etiam iaculis nunc ac metus. Praesent nec nisl a purus blandit viverra. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Fusce ac felis sit amet ligula pharetra condimentum.
Ikoner
Heading
Phasellus dolor. Nam ipsum risus, rutrum vitae, vestibulum eu, molestie vel, lacus. Etiam ultricies nisi vel augue. Suspendisse pulvinar, augue ac venenatis condimentum, sem libero volutpat nibh, nec pellentesque velit pede quis nunc.
Vivamus euismod mauris. Duis lobortis massa imperdiet quam. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Sed cursus turpis vitae tortor.
Etiam iaculis nunc ac metus. Praesent nec nisl a purus blandit viverra. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Fusce ac felis sit amet ligula pharetra condimentum.
Heading
Phasellus dolor. Nam ipsum risus, rutrum vitae, vestibulum eu, molestie vel, lacus. Etiam ultricies nisi vel augue. Suspendisse pulvinar, augue ac venenatis condimentum, sem libero volutpat nibh, nec pellentesque velit pede quis nunc.
The Impilo Health Diamond
The Impilo Health Diamond represents the four key health impact dimensions that we take into consideration in all investments. Any new investment must align with or have the potential to align with one or more of the dimensions to be deemed attractive.
Improve quality of care
We look for companies with products or services that:
- Provide positive treatment outcomes for patients and/or individuals
- Enable companies in the healthcare system to provide higher quality of care, e.g. better patient outcomes and improved quality of treatments
- Are tailored to the specific needs of individual patients and customers
- Improve processes and quality standards in the broader healthcare value chain, e.g. by ensuring products are safe to use compared to alternative treatments
Increase availability of care
We look for companies with products or services that:
- Make healthcare services more easily available or accessible to the people who need them at the time they need them (e.g. by increasing opening hours or opening of new facilities in unserved areas)
- Bring novel treatments to people who did not have access to these treatments before
- Provide scalable solutions (e.g. digital health), which reduce the dependency on in-clinic care
- Help increase capacity within the healthcare sector (e.g. new facilities, increase in healthcare workers etc.)
Lower cost of care
We look for companies with products or services that introduce critical efficiencies and cost-saving benefits compared to alternatives – either directly for patients/individuals and/or for healthcare companies or organisations that purchase them.
Prevent need for care
- Help people not get sick in the first place, e.g., through improved lifestyle choices (exercise, nutrition, etc.) – Primary prevention
- Help detect current or potential diseases early on and prevent them from getting worse – Secondary prevention
Improve quality of care
We look for companies with products or services that:
- Provide positive treatment outcomes for patients and/or individuals
- Enable companies in the healthcare system to provide higher quality of care, e.g. better patient outcomes and improved quality of treatments
- Are tailored to the specific needs of individual patients and customers
- Improve processes and quality standards in the broader healthcare value chain, e.g. by ensuring products are safe to use compared to alternative treatments
Increase availability of care
We look for companies with products or services that:
- Make healthcare services more easily available or accessible to the people who need them at the time they need them (e.g. by increasing opening hours or opening of new facilities in unserved areas)
- Bring novel treatments to people who did not have access to these treatments before
- Provide scalable solutions (e.g. digital health), which reduce the dependency on in-clinic care
- Help increase capacity within the healthcare sector (e.g. new facilities, increase in healthcare workers etc.)
Lower cost of care
We look for companies with products or services that introduce critical efficiencies and cost-saving benefits compared to alternatives – either directly for patients/individuals and/or for healthcare companies or organisations that purchase them.
Prevent need for care
- Help people not get sick in the first place, e.g., through improved lifestyle choices (exercise, nutrition, etc.) – Primary prevention
- Help detect current or potential diseases early on and prevent them from getting worse – Secondary prevention
Heading
Phasellus dolor. Nam ipsum risus, rutrum vitae, vestibulum eu, molestie vel, lacus. Etiam ultricies nisi vel augue. Suspendisse pulvinar, augue ac venenatis condimentum, sem libero volutpat nibh, nec pellentesque velit pede quis nunc.
Vivamus euismod mauris. Duis lobortis massa imperdiet quam. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Sed cursus turpis vitae tortor.
Etiam iaculis nunc ac metus. Praesent nec nisl a purus blandit viverra. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Fusce ac felis sit amet ligula pharetra condimentum.
Heading
Phasellus dolor. Nam ipsum risus, rutrum vitae, vestibulum eu, molestie vel, lacus. Etiam ultricies nisi vel augue. Suspendisse pulvinar, augue ac venenatis condimentum, sem libero volutpat nibh, nec pellentesque velit pede quis nunc.
Vivamus euismod mauris. Duis lobortis massa imperdiet quam. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Sed cursus turpis vitae tortor.
Etiam iaculis nunc ac metus. Praesent nec nisl a purus blandit viverra. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Fusce ac felis sit amet ligula pharetra condimentum.
Our team
Heading
Phasellus dolor. Nam ipsum risus, rutrum vitae, vestibulum eu, molestie vel, lacus. Etiam ultricies nisi vel augue. Suspendisse pulvinar, augue ac venenatis condimentum, sem libero volutpat nibh, nec pellentesque velit pede quis nunc.
Vivamus euismod mauris. Duis lobortis massa imperdiet quam. In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo. Sed cursus turpis vitae tortor.
Etiam iaculis nunc ac metus. Praesent nec nisl a purus blandit viverra. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Fusce ac felis sit amet ligula pharetra condimentum.
News
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.
Scantox enters transformational acquisition of QPS Neuropharmacology
Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract Research Organization (CRO) that specializes in neurodegenerative, rare diseases and mental disorders.